Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Objective</h3><p>Previous studies have established that deficiency in Nucleotide-binding and oligomerization domain (NOD)-like receptor family pyrin domain containing 6 (Nlrp6) changes the configuration of the gut microbiota, which leads to hepatic steatosis. Here, we aimed to determine the hepatic function of Nlrp6 in lipid metabolism and inflammation and its role in the development of non-alcoholic steatohepatitis (NASH).</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>Nlrp6<sup>Loxp/Loxp</sup> and hepatocyte-specific Nlrp6-knockout mice were fed a high-fat diet (HFD) or methionine-choline deficient (MCD) diet to induce fatty liver or steatohepatitis, respectively. Primary hepatocytes were isolated to further explore the underlying mechanisms <em>in vitro</em>. In addition, we used adenovirus to overexpress Nlrp6 in <em>ob/ob</em> mice to demonstrate its role in NASH.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>Hepatic Nlrp6 expression was downregulated in NASH patients and in obese mice. Hepatocyte-specific Nlrp6 deficiency promoted HFD- or MCD diet-induced lipid accumulation and inflammation, whereas Nlrp6 overexpression in <em>ob/ob</em> mice had beneficial effects. <em>In vitro</em> studies demonstrated that knockdown of Nlrp6 aggravated hepatic steatosis and inflammation in hepatocytes, but its overexpression markedly attenuated these abnormalities. Moreover, both <em>in vitro</em> and <em>in vivo</em> study demonstrated that Nlrp6 inhibited Cd36‐mediated lipid uptake. Nlrp6 deficiency-enhanced fatty acid uptake was blocked by a Cd36 inhibitor in hepatocytes. Nlrp6 ablation increased the expression of proinflammatory cytokines, likely as a result of increased NF-κB phosphorylation and activation. Mechanistically, Nlrp6 promoted the degradation of transforming growth factor-β-activated kinase 1 (TAK1)-binding protein 2/3 (TAB2/3) via a lysosomal-dependent pathway, which suppressed NF-κB activation.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>Nlrp6 may play a key role in the pathological process of NASH by inhibiting Cd36 and NF-κB pathways. It may be a potential therapeutic target for NASH.</p>

Effects of NLRP6 on the Proliferation and Activation of Human Hepatic Stellate Cells

PLK1 regulates hepatic stellate cell activation and liver fibrosis through Wnt/-catenin signalling pathway

NLRC5 Regulates TGF-β1-induced Proliferation and Activation of Hepatic Stellate Cells During Hepatic Fibrosis.

PRDX6 inhibits hepatic stellate cells activation and fibrosis via promoting MANF secretion

Potentiation of Hepatic Stellate Cell Activation by Extracellular ATP is Dependent on P2X7R-mediated NLRP3 Inflammasome Activation

P2X7 Receptor Inhibitor Suppressed Extracellular ATP/LPS-primed Human Hepatic Stellate Cells Activation Via Downregulating NLRP3 Inflammasome

The in Vitro Effects of Phospholipase D1-mTOR Axis in Liver Fibrogenesis.

Transient receptor potential channel 6 knockout ameliorates hepatic fibrosis by inhibiting the activation and proliferation of hepatic stellate cells

The Upregulation of Leucine-Rich Repeat Containing 1 Expression Activates Hepatic Stellate Cells and Promotes Liver Fibrosis by Stabilizing Phosphorylated Smad2/3

Wnt5a Promotes Cytokines Production and Cell Proliferation in Human Hepatic Stellate Cells Independent of Canonical Wnt Pathway.

Sirt6 Alleviated Liver Fibrosis by Deacetylating Conserved Lysine 54 on Smad2 in Hepatic Stellate Cells

NPM Promotes Hepatotoxin-Induced Fibrosis by Inhibiting ROS-induced Apoptosis of Hepatic Stellate Cells and Upregulating Lncmiat-Induced TGF-β2

NLR Family Pyrin Domain‐Containing 3 Inflammasome Activation in Hepatic Stellate Cells Induces Liver Fibrosis in Mice

IL-13 Induces STAT6 Phosphorylation and Promotes Fibrosis in Human Hepatic Stellate Cells

Transcription factor YY1 accelerates hepatic fibrosis development by activating NLRP3 inflammasome-mediated pyroptosis

SIRT6 Protects Against Liver Fibrosis by Deacetylation and Suppression of SMAD3 in Hepatic Stellate Cells

Hepatocyte-specific deletion of Nlrp6 in mice exacerbates the development of non-alcoholic steatohepatitis

SIRT6 Protects Against Liver Fibrosis by Deacetylation and Suppression of SMAD3 in Hepatic Stellate CellsSummary

SIRT6 Protects Against Liver Fibrosis by Negatively Regulating YAP/TAZ

EP3 enhances adhesion and cytotoxicity of NK cells toward hepatic stellate cells in a murine liver fibrosis model

Orphan Nuclear Receptor NR4A2 Inhibits Hepatic Stellate Cell Proliferation Through MAPK Pathway in Liver Fibrosis